Parkinson's Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
For people with Parkinson's disease:
- People who have been diagnosed with Parkinson's disease according to recognised medical criteria, with a disease stage rated between I and IV on a standard scale (measured while on their usual Parkinson's medication)
- People who are willing to take part on a voluntary basis
- People who are willing and able to sign a consent form, or who have a legal representative who can sign on their behalf, and who understand the purpose and methods of the study
For people without Parkinson's disease:
- People who have a normal neurological examination
- People whose medical records (both recent and past history) are available and can be reviewed by the clinical team throughout the study period
- People who are willing and able to sign a consent form
Who may not be able to join:
(Applies to both groups)
- People with significant and severe cognitive decline or intellectual disability that is not caused by Parkinson's disease
- People with certain neurological or neurodevelopmental conditions, such as cerebral palsy, epilepsy, stroke, muscular dystrophy, moderate to severe developmental delay, or spinal cord injury
- People with a fever of 38.0°C or above at the time of assessment
- People with an active illness such as flu or COVID-19 that could affect their ability to participate and impact study results
- People currently being treated with antibiotics or antiviral medications for ongoing infections such as Hepatitis C, HIV, or tuberculosis
- People with a life-threatening illness that could mean they are unable to complete the study
- People with any other neurological or health conditions that could affect the study results
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Marco Feligioni, PHD, EBRI-European Brain Research Insitute
Phone: +39 0248593242
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Quantification of α-Synuclein Isoforms (-140, -126, -112, -98) and Their SUMOylated Forms in NDEVs from Blood Samples
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.